These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7512081)

  • 21. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization of mice with human immunodeficiency virus glycoprotein gp160 peptide 315-329 induces both class I- and class II-restricted T cells: not all T cells can respond to whole molecule stimulation.
    Moore RL; Fox BS
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):51-9. PubMed ID: 7678972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
    J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement activation by gp160 glycoprotein of HIV-1.
    Thieblemont N; Haeffner-Cavaillon N; Weiss L; Maillet F; Kazatchkine MD
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):229-33. PubMed ID: 8471312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of maternal cytophilic human immunodeficiency virus (HIV)-1 V3 loop peptide-specific antibodies in infants with vertical HIV transmission.
    Wang XP; Oyaizu N; Pahwa S
    Pediatr Res; 1995 Sep; 38(3):384-9. PubMed ID: 7494664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 29. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The envelope of HIV-1 as a key component to infectivity.
    Buchbinder A
    Prog AIDS Pathol; 1990; 2():1-11. PubMed ID: 2103853
    [No Abstract]   [Full Text] [Related]  

  • 31. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Which gp160 vaccine?
    Moore J; Lewis GK; Robinson J
    Nature; 1993 Feb; 361(6412):503. PubMed ID: 7679205
    [No Abstract]   [Full Text] [Related]  

  • 33. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
    Stamatatos L; Lim M; Cheng-Mayer C
    AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potentially negative effects of AIDS vaccines based on recombinant viruses carrying HIV-1 derived envelope gene. A warning on AIDS vaccine development.
    Veljkovic V; Metlas R
    Vaccine; 1993; 11(3):291-2. PubMed ID: 8447156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
    Bona C; Nixon A; Kennedy R; Zaghouani H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1377. PubMed ID: 1466959
    [No Abstract]   [Full Text] [Related]  

  • 37. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.
    Loomis LD; Deal CD; Kersey KS; Burke DS; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):13-26. PubMed ID: 7544225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates.
    Nakamura GR; Byrn R; Rosenthal K; Porter JP; Hobbs MR; Riddle L; Eastman DJ; Dowbenko D; Gregory T; Fendly BM
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1875-85. PubMed ID: 1283308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of human epidermal Langerhans cells with HIV-1 viral envelope proteins (gp 120 and gp 160s) involves a receptor-mediated endocytosis independent of the CD4 T4A epitope.
    Dezutter-Dambuyant C; Schmitt DA; Dusserre N; Hanau D; Kolbe HV; Kieny MP; Cazenave JP; Schmitt D; Pasquali JL; Olivier R
    J Dermatol; 1991 Jul; 18(7):377-92. PubMed ID: 1724250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features.
    Gazarian KG; Palacios-Rodríguez Y; Gazarian TG; Huerta L
    Mol Immunol; 2013 Jun; 54(2):148-56. PubMed ID: 23270686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.